A double‐blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome

No abstract is available for this paper.

• Publication year

  2014

• Venue

  American Journal of Medical Genetics. Part A

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajmg.a.36653PMID 24980612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Yale–Brown Obsessive Compulsive Scale

  2015cited by this paper
• Wechsler Abbreviated Scale of Intelligence

  2014cited by this paper
• Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders

  2013cited by this paper
• Intranasal administration of oxytocin: Behavioral and clinical effects, a review

  2013cited by this paper
• Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice.

  2013cited by this paper
• Oxytocin, Vasopressin and Related Peptides in the Regulation of Behavior: The involvement of oxytocin and vasopressin in fear and anxiety

  2013cited by this paper
• Oxytocin, Vasopressin and Related Peptides in the Regulation of Behavior: The roles of vasopressin and oxytocin in aggression

  2013cited by this paper
• A simple solution for model comparison in bold imaging: the special case of reward prediction error and reward outcomes

  2013cited by this paper
• Antiaggressive activity of central oxytocin in male rats

  2013cited by this paper
• Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat

  2012cited by this paper
• Oxytocin selectively moderates negative cognitive appraisals in high trait anxious males.

  2012cited by this paper
• A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.

  2011cited by this paper
• Adolescent Oxytocin Exposure Causes Persistent Reductions in Anxiety and Alcohol Consumption and Enhances Sociability in Rats

  2011cited by this paper
• Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients

  2011cited by this paper
• Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

  2010cited by this paper
• Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans.

  2010cited by this paper
• Performance, Properties and Plasticity of Identified Oxytocin and Vasopressin Neurones In Vitro

  2010cited by this paper
• Secondary Schizophrenia: Psychosis in Prader-Willi Syndrome

  2010cited by this paper
• Neuropsychological profile of autism and the broad autism phenotype.

  2009cited by this paper
• Oxytocin and appetite.

  2008cited by this paper
• No stress please! Mechanisms of stress hyporesponsiveness of the maternal brain

  2008cited by this paper
• Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans.

  2008cited by this paper
• Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice.

  2008cited by this paper
• Oxytocin enhances the encoding of positive social memories in humans.

  2008cited by this paper
• Prader Willi Syndrome and excessive daytime sleepiness.

  2008cited by this paper
• The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment.

  2007cited by this paper
• Assessment of Hyperphagia in Prader‐Willi Syndrome

  2007cited by this paper
• Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I.

  2007cited by this paper
• Distinguishing sleepiness and fatigue: focus on definition and measurement.

  2006influential reference
• Sex-specific influences of vasopressin on human social communication

  2006cited by this paper
• Dehydration anorexia is attenuated in oxytocin-deficient mice.

  2005cited by this paper
• The effects of vasopressin on human facial responses related to social communication.

  2004cited by this paper
• Deficits in Social Attribution Ability in Prader–Willi Syndrome

  2004cited by this paper
• Neuropeptides in hypothalamic neuronal disorders.

  2004cited by this paper
• Impaired Repression at a Vasopressin Promoter Polymorphism Underlies Overexpression of Vasopressin in a Rat Model of Trait Anxiety

  2004cited by this paper
• Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment.

  2003cited by this paper
• Diagnosis of Prader-Willi syndrome.

  2003cited by this paper
• Epworth sleepiness scale?

  2003cited by this paper
• Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders

  2003cited by this paper
• Birth prevalence of Prader-Willi syndrome in Australia

  2003cited by this paper
• Psychopathology and Intellectual Disability: The Australian Child to Adult Longitudinal Study

  2003cited by this paper
• Manual for the Developmental Behaviour Checklist: Primary Carer Version (DBC-P) and Teacher Version (DBC-T) (2nd ed.)

  2002cited by this paper
• Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study.

  2002cited by this paper
• The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism.

  2001cited by this paper
• A componential view of theory of mind: evidence from Williams syndrome.

  2000cited by this paper
• The effects of oxytocin and vasopressin on partner preferences in male and female prairie voles (Microtus ochrogaster).

  1999cited by this paper
• Behavioural treatment for sleep problems in children with severe learning disabilities and challenging daytime behaviour: effect on daytime behaviour.

  1999cited by this paper
• Longitudinal course of behavioural and emotional problems of young persons with Prader-Willi, Fragile X, Williams and Down syndromes

  1999cited by this paper
• The diagnosis of Prader-Willi syndrome.

  1999cited by this paper
• Reading the Windows to the Soul: Evidence of Domain-Specific Sparing in Williams Syndrome

  1998cited by this paper
• Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects.

  1998cited by this paper
• Prader—Willi syndrome and the hypothalamus

  1997cited by this paper
• Maladaptive behavior in children with Prader-Willi syndrome, Down syndrome, and nonspecific mental retardation.

  1997cited by this paper
• Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression

  1997cited by this paper
• Obsessions and compulsions in Prader-Willi syndrome.

  1996cited by this paper
• Maladaptive behaviour in Prader-Willi syndrome in adult life.

  1996cited by this paper
• Assessment of obsessions and compulsions: Reliability, validity, and sensitivity to treatment effects.

  1995cited by this paper
• Adaptive and maladaptive behavior in Prader-Willi syndrome.

  1992cited by this paper
• Psychological Profile and Behavioral Characteristics in the Prader-Willi Syndrome

  1992cited by this paper
• A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

  1991cited by this paper
• The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

  1989cited by this paper
• Influence of oxytocin on feeding behavior in the rat.

  1989cited by this paper
• The Yale-Brown Obsessive Compulsive Scale. II. Validity.

  1989cited by this paper
• The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability

  1989cited by this paper
• NEONATAL RESPIRATORY DEPRESSION AND DELAY IN DIAGNOSIS IN PRADER‐WILLI SYNDROME

  1989cited by this paper
• Hypothalamic astrocytoma. Syndrome of hyperphagia, obesity, and disturbances of behavior and endocrine and autonomic function.

  1983cited by this paper

• Oxytocin Deficiency in Childhood and Adolescence: Clinical Features, Diagnostic Challenges and Therapeutic Perspectives

  2025cites this paper
• Complexity of the Hypothalamic Oxytocin System and its Involvement in Brain Functions and Diseases

  2025cites this paper
• Improving the diagnosis of hyperphagia in melanocortin‐4 receptor pathway diseases

  2025cites this paper
• Hyperphagia in rare melanocortin-4 receptor pathway diseases: therapeutic options and assessing treatment response

  2025cites this paper
• Barriers, Limitations, and Experiences with Clinical Trials—Treatment in Rare Diseases with Prader–Willi Syndrome as an Example

  2025cites this paper
• The burden of illness in Prader-Willi syndrome: a systematic literature review

  2025cites this paper
• The Oxytocin System and Implications for Oxytocin Deficiency in Hypothalamic-Pituitary Disease

  2025cites this paper
• Oxytocin in neurodevelopmental disorders: Autism spectrum disorder and Prader-Willi syndrome.

  2024cites this paper
• Characterising the behaviours in most severe and least severe emotional outbursts in young people

  2024cites this paper
• Is Oxytocin a Contributor to Behavioral and Metabolic Features in Prader–Willi Syndrome?

  2024cites this paper
• Clinical Efficacy Landscaping in Genetic Obesity: A Meta-analysis in Prader–Willi Syndrome (PWS)

  2024cites this paper
• The relationship between cardiac activity, behaviour and endogenous oxytocin and vasopressin in Prader-Willi Syndrome: An exploratory study.

  2024cites this paper
• Intranasal oxytocin as a treatment for obesity: safety and efficacy

  2023cites this paper
• Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial

  2023cites this paper
• Clinical Trials in Prader–Willi Syndrome: A Review

  2023cites this paper
• Management of Hyperphagia and Obesity in Prader–Willi Syndrome

  2023cites this paper
• Management of Monogenic and Syndromic Obesity.

  2023cites this paper
• Oxytocin’s Regulation of Thermogenesis May Be the Link to Prader–Willi Syndrome

  2023influential citation
• A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity

  2023cites this paper
• The relationship between endogenous oxytocin and vasopressin levels and the Prader-Willi syndrome behaviour phenotype

  2023cites this paper
• Current Treatments for Patients with Genetic Obesity

  2023cites this paper
• Hypothalamic syndrome

  2022cites this paper
• Do the diverse phenotypes of Prader-Willi syndrome reflect extremes of covariation in typical populations?

  2022cites this paper
• A Call for Drug Therapies for the Treatment of Social Behavior Disorders in Dementia: Systematic Review of Evidence and State of the Art

  2022cites this paper
• Linking oxytocin and arginine vasopressin signaling abnormalities to social behavior impairments in Prader-Willi syndrome.

  2022cites this paper
• Systematic Review: Emotion Dysregulation in Syndromic Causes of Intellectual and Developmental Disabilities.

  2022cites this paper
• Analysis of the hypothalamic oxytocin system and oxytocin receptor-expressing astrocytes in a mouse model of Prader-Willi syndrome

  2022cites this paper
• Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies

  2022cites this paper
• Prader–Willi Syndrome: Possibilities of Weight Gain Prevention and Treatment

  2022cites this paper
• Strengths and challenging behaviors in children and adolescents with Prader‐Willi syndrome: Two sides to the coin

  2022cites this paper
• Oxytocin, eating behavior, and metabolism in humans.

  2021cites this paper
• Syndrome de Prader-Willi

  2021cites this paper
• The consequences of hyperphagia in people with Prader-Willi Syndrome: A systematic review of studies of morbidity and mortality.

  2021cites this paper
• Prader-Willi syndrome: an update on obesity and endocrine problems

  2021cites this paper
• Hypothalamic neuropeptides and neurocircuitries in Prader Willi syndrome

  2021cites this paper
• Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium

  2021cites this paper
• The influence of emotional contexts on mental flexibility in Prader-Willi syndrome.

  2021cites this paper
• The Effects of Limosilactobacillus reuteri LR-99 Supplementation on Body Mass Index, Social Communication, Fine Motor Function, and Gut Microbiome Composition in Individuals with Prader–Willi Syndrome: a Randomized Double-Blinded Placebo-Controlled Trial

  2021cites this paper
• The Effects of Oxytocin on Appetite Regulation, Food Intake and Metabolism in Humans

  2021cites this paper
• Prader-Willi syndrome: Hormone therapies.

  2021cites this paper
• Old Paradoxes and New Opportunities for Appetite Control in Obesity.

  2021cites this paper
• Anti-Obesity Medication Use in Children and Adolescents with Prader–Willi Syndrome: Case Review and Literature Search

  2021cites this paper
• Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial.

  2020cites this paper
• Hypothalamic Neuropeptide Brain Protection: Focus on Oxytocin

  2020cites this paper
• IL CONTROLLO NEUROENDOCRINO DEL COMPORTAMENTO ALIMENTARE

  2020influential citation
• The sociability spectrum: evidence from reciprocal genetic copy number variations

  2020cites this paper
• The Role of Intranasal Oxytocin on Social Cognition: an Integrative Human Lifespan Approach

  2020cites this paper
• MECHANISMS IN ENDOCRINOLOGY: Update on treatments for patients with genetic obesity.

  2020cites this paper
• Behavioral and Dietary Management for Adults with Prader–Willi Syndrome in a Residential Setting

  2020cites this paper
• Pharmacotherapy in pediatric obesity: current evidence and landscape.

  2020cites this paper
• Prader-Willi syndrome: molecular mechanism and epigenetic therapy.

  2020cites this paper
• Oxytocin in young children with Prader‐Willi syndrome: Results of a randomized, double‐blind, placebo‐controlled, crossover trial investigating 3 months of oxytocin

  2020cites this paper
• Behavioral and Dietary Management for Adults with Prader–Willi Syndrome in a Residential Setting

  2020cites this paper
• The impact of early life stress on the central oxytocin system and susceptibility for drug addiction: Applicability of oxytocin as a pharmacotherapy.

  2020cites this paper
• Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review.

  2020influential citation
• Posterior Pituitary Hormones

  2020cites this paper
• Brain-Derived Neurotrophic Factor and Oxytocin Signaling in Association With Clinical Symptoms in Adolescent Inpatients With Anorexia Nervosa—A Longitudinal Study

  2020cites this paper
• Small molecule inhibitors of G9a reactivate the maternal PWS genes in Prader-Willi-Syndrome patient derived neural stem cells and differentiated neurons

  2019cites this paper
• The Global Prader–Willi Syndrome Registry: Development, Launch, and Early Demographics

  2019cites this paper
• Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review

  2019cites this paper
• Investigation of the relationship between electrodermal and behavioural responses to executive tasks in Prader-Willi syndrome: An event-related experiment.

  2019cites this paper
• Clinical, molecular genetics and therapeutic aspects of syndromic obesity

  2019cites this paper
• Is Intranasal Oxytocin an Effective Treatment for Reducing Disruptive Behavior in Individuals with Prader-Willi Syndrome?

  2019influential citation
• Metabolic Effects of Oxytocin.

  2019cites this paper
• Preclinical Testing in Translational Animal Models of Prader-Willi Syndrome: Overview and Gap Analysis

  2019cites this paper
• A multidisciplinary approach to the clinical management of Prader–Willi syndrome

  2019cites this paper
• Design of Oxytocin Analogs.

  2019cites this paper
• Oxytocin therapy in hypopituitarism: Challenges and opportunities

  2018cites this paper
• The Anorexigenic Neural Pathways of Oxytocin and Their Clinical Implication

  2018cites this paper
• Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis.

  2018cites this paper
• [Neuropsychiatric aspects of Prader-Willi syndrome – a review].

  2018cites this paper
• Oxytocin and Eating Disorders: A Narrative Review on Emerging Findings and Perspectives

  2018cites this paper
• Oxytocin and Prader-Willi Syndrome.

  2018cites this paper
• No side-effects of single intranasal oxytocin administration in middle childhood

  2018cites this paper
• Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.

  2018cites this paper
• Evidence for intranasal oxytocin delivery to the brain: recent advances and future perspectives.

  2018cites this paper
• New treatment modalities for obesity.

  2018cites this paper
• Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)

  2018cites this paper
• Obesity management in Prader–Willi syndrome: current perspectives

  2018cites this paper
• Pharmacological and non-pharmacological interventions for non-respiratory sleep disturbance in children with neurodisabilities: a systematic review.

  2018cites this paper
• The potential of oxytocin for the treatment of hyperphagia in Prader-Willi Syndrome

  2018cites this paper
• First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma

  2017cites this paper
• Current Treatments of Prader-Willi Syndrome: A Systematic Review

  2017influential citation
• The effects of oxytocin on eating behaviour and metabolism in humans

  2017cites this paper
• Describing some behavioural animal models of anxiety and their mechanistics with special reference to oxidative stress and oxytocin relevance

  2017cites this paper
• Oxytocin system dysfunction as a common mechanism underlying metabolic syndrome and psychiatric symptoms in schizophrenia and bipolar disorders.

  2017cites this paper
• Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder

  2017cites this paper
• A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research

  2017influential citation
• Oxytocin and potential benefits for obesity treatment

  2017cites this paper
• Unsupervised data-driven stratification of mentalizing heterogeneity in autism

  2017cites this paper
• A review of clinical trials of oxytocin in Prader–Willi syndrome

  2017cites this paper
• Oxytocin Treatment May Improve Infant Feeding and Social Skills in Prader-Willi Syndrome

  2017cites this paper
• Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward

  2017cites this paper
• Current findings on the role of oxytocin in the regulation of food intake.

  2017cites this paper
• Oxytocin treatment in children with Prader–Willi syndrome: A double‐blind, placebo‐controlled, crossover study

  2017influential citation
• Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.

  2016cites this paper
• New Treatment Perspectives in Prader-Willi syndrome

  2016cites this paper
• The effects of Caralluma Fimbriata on appetite behaviour and associated neural pathways in Prader-Willi syndrome

  2016cites this paper
• Explorer Intranasal oxytocin : myths and delusions

  2016cites this paper
• Short Review on the Aggressive Behaviour: Genetical, Biological Aspects and Oxytocin Relevance

  2016cites this paper